Metoclopramide intranasal

Drug Profile

Metoclopramide intranasal

Alternative Names: Emitasol; EVK 001; Gimoti™; Pramidin

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Evoke Pharma; Questcor Pharmaceuticals
  • Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Phase III Diabetic gastroparesis
  • Discontinued Gastroparesis

Most Recent Events

  • 15 Mar 2017 Evoke Pharma announces intention to submit a 505(b) NDA for Diabetic gastroparesis to the US FDA by late 017 or early 018 (913071)
  • 15 Mar 2017 Evoke Pharma plans a comparative exposure pharmacokinetic trial for metoclopramide nasal spray in healthy volunteers
  • 04 Jan 2017 Safety and efficacy data from a phase III trial in Diabetic gastroparesis released by Evoke Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top